Newborns have sterile guts that gradually become colonized with bacteria. In formula-fed infants, certain bacteria help break down bilirubin so it cannot be reabsorbed. In breastfed infants, the gut flora is different; the absence of specific bacteria early on may allow more bilirubin to remain in a state where it can be reabsorbed.
While breast milk jaundice can last for several weeks or even months, it is generally considered a benign condition that does not cause harm (kernicterus) in healthy, thriving infants. However, high bilirubin levels should always be evaluated by a pediatrician to rule out other pathological causes.
Recent studies indicate that genetic variations in the mother or the infant may play a role. what causes breast milk jaundice
The symptoms of breast milk jaundice typically appear in the first week of life and may include:
Breast milk jaundice is diagnosed based on a combination of clinical evaluation, laboratory tests, and exclusion of other causes of jaundice. The following tests may be performed: Newborns have sterile guts that gradually become colonized
is a common condition in newborns characterized by elevated levels of bilirubin that persist after the first week of life. It is distinct from "breastfeeding jaundice," which is caused by insufficient milk intake.
It is critical to distinguish between "breast milk jaundice" and "breastfeeding jaundice" (also known as suboptimal intake jaundice), as they have different causes and management strategies. Breast Milk Jaundice - StatPearls - NCBI Bookshelf While breast milk jaundice can last for several
| Component in Breast Milk | Proposed Mechanism | Evidence Strength | |--------------------------|--------------------|-------------------| | | This enzyme de-conjugates bilirubin in the infant's gut. Normally, conjugated bilirubin (excreted in bile) is passed in stool. Beta-glucuronidase reverses this, turning it back into fat-soluble unconjugated bilirubin, which is reabsorbed from the intestine (enterohepatic circulation). | Strongest – Levels are 10–20x higher in milk of mothers whose infants develop BMJ. Activity correlates with bilirubin levels. | | 2. Non-esterified long-chain polyunsaturated fatty acids (e.g., EPA, DHA) | These fatty acids and their metabolites (like sulfated steroids) directly inhibit UGT1A1 enzyme activity in hepatocyte assays. The inhibition is reversible and dose-dependent. | Moderate-strong – Seen in vitro and in animal models. Explains why BMJ resolves when milk is temporarily stopped (heat-labile component? No – fatty acids are heat-stable, but other factors differ). | | 3. Interleukin-1 beta (IL-1β) & TNF-alpha | Pro-inflammatory cytokines in some milk may downregulate UGT1A1 gene expression or increase intestinal permeability, enhancing bilirubin reabsorption. | Emerging – Higher in BMJ-associated milk; may act synergistically with fatty acids. | | 4. Epidermal Growth Factor (EGF) | EGF delays maturation of intestinal tight junctions in neonates, paradoxically increasing paracellular absorption of unconjugated bilirubin from the gut lumen. | Moderate – EGF is higher in BMJ milk; animal knockouts show reduced jaundice. | | 5. Pregnanediol (a progesterone metabolite) | Earlier hypothesis (1970s) suggested this steroid inhibits UGT1A1. Later studies found no consistent elevation in BMJ milk. | Weak / historical – Largely discarded as primary cause. |
